Biodesix reaches halfway point of $25M equity offering
BOULDER — Biodesix Inc., a developer and manufacturer of blood-test kits for cancer diagnostics, has raised equity capital.
The Boulder-based bioscience company filed a notice with the U.S. Securities and Exchange Commission saying that it had sold nearly $13.2 million in equity out of $25.3 million it’s offering.
The first date of sale was April 12, and the form was filed April 21. Biodesix did not return multiple calls for comment.
SPONSORED CONTENT
People Powered: Preparing Longmont Businesses for Economic Success
Longmont Chamber and FNBO present People Powered on April 24, 2024, aiming to inform business owners about workforce development, housing, and transportation issues.
The funding follows several international partnerships Biodesix has made so far this year. In March, the firm signed a deal with Tel Aviv-based Progenetics to market and distribute its advanced-lung-cancer blood tests in Israel. In January, it announced that Bioyong Technology Co. Ldt., of China, would be a partner in the commercialization of blood tests for non-small cell lung cancer.
BOULDER — Biodesix Inc., a developer and manufacturer of blood-test kits for cancer diagnostics, has raised equity capital.
The Boulder-based bioscience company filed a notice with the U.S. Securities and Exchange Commission saying that it had sold nearly $13.2 million in equity out of $25.3 million it’s offering.
The first date of sale was April 12, and the form was filed April 21. Biodesix did not return multiple calls for comment.
The funding follows several international partnerships Biodesix has made so far this year. In March, the firm signed a deal with…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
